Nano Research

, Volume 8, Issue 5, pp 1505–1521

A prospective cancer chemo-immunotherapy approach mediated by synergistic CD326 targeted porous silicon nanovectors

  • Mohammad-Ali Shahbazi
  • Neha Shrestha
  • Ermei Mäkilä
  • Francisca Araújo
  • Alexandra Correia
  • Tomás Ramos
  • Bruno Sarmento
  • Jarno Salonen
  • Jouni Hirvonen
  • Hélder A. Santos
Research Article

Abstract

Combination therapy via nanoparticulate systems has already been proposed as a synergistic approach for cancer treatment. Herein, undecylenic acid modified thermally hydrocarbonized porous silicon nanoparticles (UnTHCPSi NPs) loaded with sorafenib and surface-biofunctionalized with anti-CD326 antibody (Ab) were developed for cancer chemo-immunotherapy in MCF-7 and MDA-MB-231 breast cancer cells. The cytocompatibility study showed no significant toxicity for the bare and antibody-conjugated UnTHCPSi (Un-Ab) NPs at concentrations lower than 200 μg·mL−1. Compared to the bare UnTHCPSi, Un-Ab NPs loaded with sorafenib reduced the premature drug release in plasma, increasing the probability of proper drug targeting. In addition, high cellular interaction and subsequent internalization of the Un-Ab NPs into the cells expressing CD326 antigen demonstrated the possibility of improving antigen-mediated endocytosis via CD326 targeting. While an in vitro antitumor study revealed a higher inhibitory effect of the sorafenib-loaded Un-Ab NPs compared to the drug-loaded UnTHCPSi NPs in the CD326 positive MCF-7 cells, there was no difference in the anti-proliferation impact of both the abovementioned NPs in the CD326 negative MDA-MB-231 cells, suggesting CD326 as an appropriate receptor for Ab-mediated drug delivery. It was also shown that the anti-CD326 Ab can act as an immunotherapeutic agent by inducing antibody dependent cellular cytotoxicity and enhancing the interaction of effector immune and cancer cells for subsequent phagocytosis and cytokine secretion. Hence, the developed nanovectors can be applied for simultaneous tumor-selective drug targeting and immunotherapy.

Keywords

CD326 antibody porous silicon nanoparticles chemo-immunotherapy breast cancer drug targeting 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Supplementary material

12274_2014_635_MOESM1_ESM.pdf (1.8 mb)
Supplementary material, approximately 1.04 MB.

Copyright information

© Tsinghua University Press and Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Mohammad-Ali Shahbazi
    • 1
  • Neha Shrestha
    • 1
  • Ermei Mäkilä
    • 1
    • 2
  • Francisca Araújo
    • 1
    • 3
    • 4
  • Alexandra Correia
    • 1
  • Tomás Ramos
    • 5
  • Bruno Sarmento
    • 3
    • 6
  • Jarno Salonen
    • 2
  • Jouni Hirvonen
    • 1
  • Hélder A. Santos
    • 1
  1. 1.Division of Pharmaceutical Chemistry and Technology, Faculty of PharmacyUniversity of HelsinkiHelsinkiFinland
  2. 2.Laboratory of Industrial Physics, Department of Physics and AstronomyUniversity of TurkuTurkuFinland
  3. 3.INEB — Instituto de Engenharia Biomédica, NewTherapies GroupUniversidade do PortoPortoPortugal
  4. 4.ICBAS — Instituto Ciências Biomédicas Abel SalazarUniversity of PortoPortoPortugal
  5. 5.Faculty of PharmacyUniversity of CoimbraCoimbraPortugal
  6. 6.IINFACTS — Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Instituto Superior de Ciências da Saúde-Norte, Department of Pharmaceutical SciencesCESPU, Rua Central de GandraGandraPortugal

Personalised recommendations